Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819007 · ClinicalTrials.gov registry record · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
A Phase 3 study of Ovarian Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 582
- Enrollment target
- 20
- Study locations
NCT06819007 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 582 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06819007, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 582 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
Florida
- Broward Health Medical Center - Fort Lauderdale
- Jupiter Medical Center - Jupiter
- Mount Sinai Medical Center - Miami Beach
- AdventHealth Cancer Institute - Orlando
- Woman's Care FL - St. Petersburg
Michigan
- Trinity Health St. Joseph Mercy Ann Arbor - Ann Arbor
- Corewell Health - Grand Rapids
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York
- Icahn School of Medicine at Mount Sinai - New York
California
- Scripps Clinic - La Jolla
Georgia
- Nancy N. & J.C Lewis Cancer & Research Pavillion- St. Josephs/ Candler Health System - Savannah
Indiana
- Indiana University - Indianapolis
Louisiana
- Trials365 LLC - Shreveport
Maryland
- Greater Baltimore Medical Center - Towson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2032-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06819007
The ClinicalTrials.gov registry entry for NCT06819007 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (20% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT06819007 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06819007 about?
NCT06819007 is a clinical study titled "Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)". This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-...
What is the current status of trial NCT06819007?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 582 participants. The study started on 2025-03-19. Estimated completion is 2032-01-31.
What conditions does trial NCT06819007 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06819007?
The interventions under investigation include: Bevacizumab (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06819007?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819007 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.